Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old.

Next Previous
X
Search
Trial Profile

A National, Open-Label, Multicenter, Randomized, Comparative Phase III Study of Induction Treatment With Melphalan/Prednisone/Velcade Versus Thalidomide Prednisone / Velcade and Maintenance Treatment With Thalidomide / Velcade Versus Prednisone / Velcade in Untreated Patients With Multiple Myeloma More Than 65 Years Old.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 21 Apr 2020

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bortezomib (Primary) ; Prednisone (Primary) ; Thalidomide (Primary) ; Melphalan
  • Indications Multiple myeloma
  • Focus Pharmacogenomic; Therapeutic Use

    • Most Recent Events

    • 16 Apr 2020 Results of PETHEMA/GEM2012MENOS65 trial (n=285) and four PETHEMA/GEM protocols (n=1252) (GEM2012MENOS65, GEM2000 (n=475) and GEM2005MENOS65(n=275) and GEM2005MAS65(n=217))published in the Blood
    • 04 Dec 2018 Results of matching-adjusted Indirect comparison using VISTA, ALCYONE, GIMEMA-QW, GIMEMA MM-03-05 and GEM2005MAS65 trials presented at the 60th Annual Meeting and Exposition of the American Society of Hematology
    • 25 Jun 2017 Results validating the use of Serum-Free Light-Chains (sFLC) assay in patients being treated in GEM/PETHEMA clinical trials (GEM05menos65, GEM05MAS65, GEM2010MAS65 and GEM2012menos65), presented at the 22nd Congress of the European Haematology Association.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top